Rockwell Medical (RMTI) Q2 2025 earnings summary

Executive summary

• Q2 2025 net sales declined 38% year-over-year to $16.1 million, mainly due to the largest customer transitioning away, but new and renewed multi-year contracts, including a multimillion-dollar agreement with Innovative Renal Care, were secured.

• Cash position improved to $18.4 million at quarter end, with $1.8 million in positive operating cash flow.

• Over 80% of customers are now under long-term contracts, reducing concentration risk and supporting future revenue stability.

• The organization was right-sized and invested in automation to maintain gross margins.

• The company is focusing on securing long-term contracts and filling the revenue gap after the customer transition.

Financial highlights

• Q2 2025 net sales were $16.1 million, down 38% year-over-year; gross profit was $2.5 million, a 45% decrease; gross margin was 16%, down from 18% in Q2 2024.

• Net loss for Q2 2025 was $1.5 million, or $(0.05) per share, compared to net income of $0.3 million in Q2 2024.

• Adjusted EBITDA for Q2 2025 was -$0.2 million, improving from -$0.4 million in Q1 2025.

• Six-month net sales ended June 30, 2025 were $35.0 million, a 28% decrease year-over-year; net loss for the six months was $3.0 million.

• Cash, cash equivalents, and investments totaled $18.4 million as of June 30, 2025.

Outlook and guidance

• 2025 guidance reiterated: net sales between $65 million and $70 million, gross margin 16%-18%, adjusted EBITDA between -$0.5 million and +$0.5 million.

• Management believes current liquidity is sufficient for at least the next twelve months.

• Ongoing negotiations with DaVita for a long-term supply agreement could impact late 2025 and future financials.

• The company may raise additional capital via its $21.1 million ATM facility or other financings if needed.

• Expansion in the Western U.S. is seen as a $100 million opportunity, with more clarity expected later in the year.